PubRank

John T Isaacs

Author PubWeight™ 99.85‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014 12.29
2 Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004 6.82
3 A history of prostate cancer treatment. Nat Rev Cancer 2002 2.46
4 The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells. Cancer Res 2008 2.29
5 Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003 2.16
6 Homozygous deletions and recurrent amplifications implicate new genes involved in prostate cancer. Neoplasia 2008 2.07
7 Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006 2.02
8 Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003 1.73
9 The current state of preclinical prostate cancer animal models. Prostate 2008 1.68
10 Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells. Cancer Res 2006 1.65
11 Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells. Proc Natl Acad Sci U S A 2006 1.61
12 Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003 1.60
13 Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res 2006 1.60
14 In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004 1.57
15 The SERCA pump as a therapeutic target: making a "smart bomb" for prostate cancer. Cancer Biol Ther 2005 1.56
16 Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007 1.55
17 PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor. Prostate 2006 1.55
18 Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells. Cancer Res 2004 1.50
19 Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Mol Cancer Ther 2012 1.48
20 Androgen receptor outwits prostate cancer drugs. Nat Med 2004 1.44
21 A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007 1.41
22 Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012 1.29
23 Potent and selective peptidyl boronic acid inhibitors of the serine protease prostate-specific antigen. Chem Biol 2008 1.24
24 Role of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005 1.23
25 Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug. J Natl Cancer Inst 2012 1.23
26 Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 2007 1.20
27 Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 2009 1.18
28 Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010 1.14
29 DNA licensing as a novel androgen receptor mediated therapeutic target for prostate cancer. Endocr Relat Cancer 2009 1.12
30 Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells. Bioorg Med Chem 2006 1.10
31 The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007 1.10
32 A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res 2006 1.10
33 Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One 2010 1.09
34 Quantification of Mesenchymal Stem Cells (MSCs) at sites of human prostate cancer. Oncotarget 2013 1.06
35 Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 2010 1.01
36 Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 2010 1.00
37 Molecular characterization of an improved vector for evaluation of the tumor suppressor versus oncogene abilities of the androgen receptor. Prostate 2004 0.99
38 Of mice and men--warning: intact versus castrated adult male mice as xenograft hosts are equivalent to hypogonadal versus abiraterone treated aging human males, respectively. Prostate 2013 0.98
39 Enzymatically active prostate-specific antigen promotes growth of human prostate cancers. Prostate 2011 0.97
40 Mesenchymal stem cells as a vector for the inflammatory prostate microenvironment. Endocr Relat Cancer 2013 0.96
41 A Trojan horse in drug development: targeting of thapsigargins towards prostate cancer cells. Anticancer Agents Med Chem 2009 0.96
42 Prostate-specific antigen (PSA) is activated by KLK2 in prostate cancer ex vivo models and in prostate-targeted PSA/KLK2 double transgenic mice. Prostate 2010 0.96
43 Amino acid containing thapsigargin analogues deplete androgen receptor protein via synthesis inhibition and induce the death of prostate cancer cells. Mol Cancer Ther 2009 0.95
44 Androgens and prostate cancer: are the descriptors valid? Cancer Biol Ther 2005 0.95
45 Prostate-specific antigen is a "chymotrypsin-like" serine protease with unique P1 substrate specificity. Biochemistry 2009 0.94
46 Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate 2011 0.94
47 Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. Prostate 2006 0.93
48 Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. J Nucl Med 2009 0.92
49 Development of prostate cancer treatment: the good news. Prostate 2004 0.91
50 Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. Prostate 2003 0.90
51 Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR/β-catenin/TCF-4 complex inhibition of c-MYC transcription. Prostate 2014 0.89
52 Benzoylphenylurea sulfur analogues with potent antitumor activity. J Med Chem 2006 0.89
53 Mechanistic insights into the inhibition of prostate specific antigen by beta-lactam class compounds. Proteins 2008 0.88
54 Dual-label centromere and telomere FISH identifies human, rat, and mouse cell contribution to Multispecies recombinant urogenital sinus xenografts. Prostate 2009 0.87
55 Applying linear interaction energy method for rational design of noncompetitive allosteric inhibitors of the sarco- and endoplasmic reticulum calcium-ATPase. J Med Chem 2005 0.86
56 Molecular characterization of the commonly used human androgen receptor expression vector, pSG5-AR. Prostate 2004 0.86
57 Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 2005 0.85
58 Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg Med Chem 2007 0.85
59 Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer. Prostate 2008 0.85
60 Human prostate cancer initiating cells isolated directly from localized cancer do not form prostaspheres in primary culture. Prostate 2012 0.82
61 Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. Cancer Res 2002 0.82
62 Suppression of mutant androgen receptors by flutamide. Int J Urol 2009 0.82
63 The "infectious" nature of human prostate cancer: a cautionary note. Oncotarget 2011 0.82
64 Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint. Cancer Biol Ther 2007 0.81
65 Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors. Prostate 2007 0.81
66 Molecular insights into substrate specificity of prostate specific antigen through structural modeling. Proteins 2009 0.81
67 A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett 2002 0.81
68 Total synthesis of two novel subpicomolar sarco/endoplasmatic reticulum Ca2+-ATPase inhibitors designed by an analysis of the binding site of thapsigargin. J Med Chem 2005 0.80
69 Nonimmunosuppressant immunophilin ligand GPI-1046 does not promote in vitro growth of prostate cancer cells. Urology 2005 0.80
70 Engineering enzymatically activated "molecular grenades" for cancer. Oncotarget 2012 0.80
71 Defining regulatory elements in the human KAI1 (CD 82) metastasis suppressor gene. Prostate 2003 0.78
72 Cytotoxic phenylpropanoids and an additional thapsigargin analogue isolated from Thapsia garganica. Phytochemistry 2006 0.77
73 Pharmacokinetics and toxicology of a fibroblast activation protein (FAP)-activated prodrug in murine xenograft models of human cancer. Prostate 2014 0.77
74 Androgen withdrawal fails to induce detectable tissue hypoxia in the rat prostate. Prostate 2014 0.75
75 The alchemy of Jargon: etymologies of urologic neologisms: number 1--introduction to the series. Prostate 2009 0.75